Logo image of MAK.DE

MATERNUS-KLINIKEN AG (MAK.DE) Stock Fundamental Analysis

Europe - FRA:MAK - DE0006044001 - Common Stock

1.11 EUR
-0.02 (-1.77%)
Last: 9/22/2025, 7:00:00 PM
Fundamental Rating

1

MAK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 29 industry peers in the Health Care Providers & Services industry. MAK may be in some trouble as it scores bad on both profitability and health. MAK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MAK had negative earnings in the past year.
In the past year MAK had a positive cash flow from operations.
In the past 5 years MAK always reported negative net income.
Each year in the past 5 years MAK had a positive operating cash flow.
MAK.DE Yearly Net Income VS EBIT VS OCF VS FCFMAK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

MAK has a Return On Assets of -9.41%. This is amonst the worse of the industry: MAK underperforms 89.66% of its industry peers.
Industry RankSector Rank
ROA -9.41%
ROE N/A
ROIC N/A
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAK.DE Yearly ROA, ROE, ROICMAK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

1.3 Margins

The Gross Margin of MAK (86.65%) is better than 86.21% of its industry peers.
In the last couple of years the Gross Margin of MAK has remained more or less at the same level.
MAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
MAK.DE Yearly Profit, Operating, Gross MarginsMAK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

0

2. Health

2.1 Basic Checks

MAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MAK has about the same amount of shares outstanding.
The number of shares outstanding for MAK remains at a similar level compared to 5 years ago.
MAK has a worse debt/assets ratio than last year.
MAK.DE Yearly Shares OutstandingMAK.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MAK.DE Yearly Total Debt VS Total AssetsMAK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.39, we must say that MAK is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.39, MAK is doing worse than 79.31% of the companies in the same industry.
The Debt to FCF ratio of MAK is 13.53, which is on the high side as it means it would take MAK, 13.53 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 13.53, MAK is doing worse than 62.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 13.53
Altman-Z -1.39
ROIC/WACCN/A
WACC4.1%
MAK.DE Yearly LT Debt VS Equity VS FCFMAK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

MAK has a Current Ratio of 0.13. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.13, MAK is not doing good in the industry: 86.21% of the companies in the same industry are doing better.
MAK has a Quick Ratio of 0.13. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of MAK (0.13) is worse than 86.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
MAK.DE Yearly Current Assets VS Current LiabilitesMAK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

MAK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.72%.
MAK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.43%.
MAK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.73% yearly.
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.4%
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%-44.41%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAK.DE Yearly Revenue VS EstimatesMAK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MAK.DE Yearly EPS VS EstimatesMAK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 -0.02 -0.04 -0.06

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MAK. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAK.DE Price Earnings VS Forward Price EarningsMAK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

75.86% of the companies in the same industry are cheaper than MAK, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MAK indicates a rather cheap valuation: MAK is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 1.68
EV/EBITDA 19.32
MAK.DE Per share dataMAK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MAK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MATERNUS-KLINIKEN AG

FRA:MAK (9/22/2025, 7:00:00 PM)

1.11

-0.02 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-21 2025-07-21
Earnings (Next)09-30 2025-09-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners81.7%
Ins Owner ChangeN/A
Market Cap23.28M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.2
P/FCF 1.68
P/OCF 1.54
P/B N/A
P/tB N/A
EV/EBITDA 19.32
EPS(TTM)-0.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.66
FCFY59.53%
OCF(TTM)0.72
OCFY64.76%
SpS5.44
BVpS-3.19
TBVpS-3.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.65%
FCFM 12.15%
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
F-Score5
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 13.53
Debt/EBITDA 6.78
Cap/Depr 9.69%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion 146.75%
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -1.39
F-Score5
WACC4.1%
ROIC/WACCN/A
Cap/Depr(3y)22.85%
Cap/Depr(5y)18.44%
Cap/Sales(3y)2.27%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.4%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%-44.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1062.29%
FCF growth 3Y-3.29%
FCF growth 5Y-1.66%
OCF growth 1Y497.23%
OCF growth 3Y-4.38%
OCF growth 5Y-1.22%